Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Franke, Andreas ^a   Niederfellner, Gerhard J ^a   Klein, Christian ^a,b   Burtscher, Helmut ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b Roche Glycart AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIBODY; B LYMPHOCYTE RECEPTOR; CD20 ANTIBODY; CD20 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROTEIN KINASE SYK; SMALL INTERFERING RNA; TRANSCRIPTOME; ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE ACTIVATION; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE INTERACTION; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; NONHODGKIN LYMPHOMA; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; CLUSTER ANALYSIS; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; CELL LINE, TUMOR; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOMA, NON-HODGKIN; MICROARRAY ANALYSIS; RECEPTORS, ANTIGEN, B-CELL; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 79951999551     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016596     Document Type: Article

References (47)

1. Harwood NE, Batista FD, (2008) New insights into the early molecular events underlying B cell activation. Immunity 28: 609-619.
2. Chaouchi N, Vazquez A, Galanaud P, Leprince C, (1995) B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. J Immunol 154: 3096-3104.
3. Batlle A, Papadopoulou V, Gomes AR, Willimott S, Melo JV, et al. (2009) CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression. Mol Immunol 46: 1727-1735.
4. Young RM, Turner BC, Refaeli Y, (2008) B-cell receptor signaling in the genesis and maintenance of B-cell lymphoma. Future Oncol 4: 591-594.
5. Perosa F, Prete M, Racanelli V, Dammacco F, (2010) CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 267: 260-277.
6. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, et al. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115: 4393-4402.
7. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J, (2002) The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99: 1314-1319.
8. Glennie MJ, French RR, Cragg MS, Taylor RP, (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44: 3823-3837.
9. Eeva J, Pelkonen J, (2004) Mechanisms of B cell receptor induced apoptosis. Apoptosis 9: 525-531.
10. Mayumi M, Ohshima Y, Hata D, Kim KM, Heike T, et al. (1995) IgM-mediated B cell apoptosis. Crit Rev Immunol 15: 255-269.
11. Mimori K, Kiyokawa N, Taguchi T, Suzuki T, Sekino T, et al. (2003) Costimulatory signals distinctively affect. Leukemia 17: 1164-1174.
12. Mizuno T, Rothstein TL, (2005) B cell receptor (BCR) cross-talk: CD40 engagement creates an alternate pathway for BCR signaling that activates I kappa B kinase/I kappa B alpha/NF-kappa B without the need for PI3K and phospholipase C gamma. J Immunol 174: 6062-6070.
13. Mizuno T, Rothstein TL, (2005) B cell receptor (BCR) cross-talk: CD40 engagement enhances BCR-induced ERK activation. J Immunol 174: 3369-3376.
14. Shan D, Ledbetter JA, Press OW, (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48: 673-683.
15. Petrie RJ, Deans JP, (2002) Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol 169: 2886-2891.
16. Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, et al. (2008) Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem 283: 16971-16984.
17. Li H, Ayer LM, Lytton J, Deans JP, (2003) Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 278: 42427-42434.
18. Polyak MJ, Li H, Shariat N, Deans JP, (2008) CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem 283: 18545-18552.
19. Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, et al. (2010) Rituximab inhibits B-cell receptor signaling. Blood 115: 985-994.
20. Cancro MP, (2009) Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 9: 657-661.
21. Saito Y, Miyagawa Y, Onda K, Nakajima H, Sato B, et al. (2008) B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells. Immunology 125: 570-590.
22. Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY, (2000) Anti-CD20- and B-cell Receptor mediated Apoptosis: Evidence for shared intracellular signaling pathways. Cancer Res 60: 7170-7176.
23. Su GH, Chen HM, Muthusamy N, Garrett-Sinha LA, Baunoch D, et al. (1997) Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B. EMBO J 16: 7118-7129.
24. Murn J, Mlinaric-Rascan I, Vaigot P, Alibert O, Frouin V, et al. (2009) A Myc-regulated transcriptional network controls B-cell fate in response to BCR triggering. BMC Genomics 10: 323.
25. Glynne R, Ghandour G, Rayner J, Mack DH, Goodnow CC, (2000) B-lymphocyte quiescence, tolerance and activation as viewed by global gene expression profiling on microarrays. Immunol Rev 176: 216-246.
26. Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, et al. (2001) Signatures of the immune response. Immunity 15: 375-385.
27. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, et al. (2006) A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 210: 67-85.
28. Kurosaki T, (2002) Regulation of B-cell signal transduction by adaptor proteins. Nat Rev Immunol 2: 354-363.
29. Wakabayashi C, Adachi T, Wienands J, Tsubata T, (2002) A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science 298: 2392-2395.
30. Horikawa K, Martin SW, Pogue SL, Silver K, Peng K, et al. (2007) Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J Exp Med 204: 759-769.
31. Cittera E, Leidi M, Buracchi C, Pasqualini F, Sozzani S, et al. (2007) The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol 178: 6616-6623.
32. Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, et al. (2009) The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 28: 3261-3273.
33. Caballero A, Katkere B, Wen XY, Drake L, Nashar TO, et al. (2006) Functional and structural requirements for the internalization of distinct BCR-ligand complexes. Eur J Immunol 36: 3131-3145.
34. Dong HY, Shahsafaei A, Dorfman DM, (2002) CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naive B cells. Leuk Lymphoma 43: 1855-1858.
35. Cittera E, Onofri C, D'Apolito M, Cartron G, Cazzaniga G, et al. (2005) Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol Immunother 54: 273-286.
36. Kluiver J, Poppema S, de JD, Blokzijl T, Harms G, et al. (2005) BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 207: 243-249.
37. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A, (2004) High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 39: 167-169.
38. Waldschmidt TJ, Tygrett LT, (1992) The low affinity IgE Fc receptor (CD23) participates in B cell activation. Adv Exp Med Biol 323: 149-156.
39. Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, et al. (2008) Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol 45: 3926-3933.
40. Rankin CT, Veri MC, Gorlatov S, Tuaillon N, Burke S, et al. (2006) CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma. Blood 108: 2384-2391.
41. Crowley JE, Stadanlick JE, Cambier JC, Cancro MP, (2009) FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation. Blood 113: 1464-1473.
42. Isnardi I, Bruhns P, Bismuth G, Fridman WH, Daeron M, (2006) The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human FcgammaRIIB and is mandatory for negative regulation of B cell activation. Immunol Lett 104: 156-165.
43. Niederer HA, Clatworthy MR, Willcocks LC, Smith KG, (2010) FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann N Y Acad Sci 1183: 69-88.
44. Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, et al. (2009) Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 113: 2508-2516.
45. Lai JY, Cox PJ, Patel R, Sadiq S, Aldous DJ, et al. (2003) Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorg Med Chem Lett 13: 3111-3114.
46. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, et al. (2003) The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 306: 1174-1181.
47. Benard G, Neutzner A, Peng G, Wang C, Livak F, et al. (2010) IBRDC2, an IBR-type E3 ubiquitin ligase, is a regulatory factor for Bax and apoptosis activation. EMBO J 29: 1458-1471.